Last reviewed · How we verify
ATG/PTCy
ATG/PTCy is a combination immunosuppressive regimen that depletes T cells and provides graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.
ATG/PTCy is a combination immunosuppressive regimen that depletes T cells and provides graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation. Used for Graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation, Hematologic malignancies undergoing allogeneic transplantation.
At a glance
| Generic name | ATG/PTCy |
|---|---|
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Immunosuppressive combination therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology/Hematology |
| Phase | FDA-approved |
Mechanism of action
Antithymocyte globulin (ATG) is a polyclonal antibody that depletes T lymphocytes, reducing the risk of graft rejection and GVHD. Post-transplant cyclophosphamide (PTCy) is a high-dose chemotherapy agent administered after transplantation that selectively eliminates alloreactive T cells while sparing hematopoietic stem cells and regulatory T cells, further preventing GVHD while maintaining graft-versus-leukemia effects.
Approved indications
- Graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation
- Hematologic malignancies undergoing allogeneic transplantation
Common side effects
- Infection
- Cytopenias
- Mucositis
- Hepatotoxicity
- Hemorrhagic cystitis
Key clinical trials
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation (PHASE3)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (PHASE2)
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (PHASE3)
- Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant (PHASE2)
- Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATG/PTCy CI brief — competitive landscape report
- ATG/PTCy updates RSS · CI watch RSS
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI